Alpha 2.0
Login Register
» Authors » W Janni

W Janni

Explore the profile of W Janni including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 96
Citations 1777
Followers 0
Related Specialties
Oncology
Gynecology & Obstetrics
General Medicine
Top 10 Co-Authors
B Rack
H Sommer
C Schindlbeck
T Fehm
P A Fasching
K Friese
M W Beckmann
S Braun
N Harbeck
A Wockel
Published In
Geburtshilfe Frauenheilkd
Ann Oncol
Arch Gynecol Obstet
Zentralbl Gynakol
Breast Cancer Res Treat
Affiliations
Soon will be listed here.
Recent Articles
1.
Replies - Letter to the Editor - "Effect of a comprehensive lifestyle intervention program on body weight and health behavior in women with breast cancer: Results from a randomized controlled trial"
Hauner D, Gunther J, Schederecker F, Donik L, Meyer D, Hermsdorfer J, et al.
Clin Nutr . 2024 Nov; 43(12):243-244. PMID: 39520784
No abstract available.
2.
Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE)
Meyer-Wilmes P, Huober J, Untch M, Blohmer J, Janni W, Denkert C, et al.
ESMO Open . 2024 Apr; 9(5):103009. PMID: 38663168
Background: The GENEVIEVE study, comparing neoadjuvant cabazitaxel versus paclitaxel in triple-negative breast cancer (TNBC) and luminal B/human epidermal growth factor receptor 2 (HER2)-negative breast cancer (BC), previously reported significant differences...
3.
The efficacy of sacituzumab govitecan and trastuzumab deruxtecan on stable and active brain metastases in metastatic breast cancer patients-a multicenter real-world analysis
Dannehl D, Jakob D, Mergel F, Estler A, Engler T, Volmer L, et al.
ESMO Open . 2024 Apr; 9(5):102995. PMID: 38636292
Background: Fifteen to thirty percent of all patients with metastatic breast cancer (MBC) develop brain metastases (BCBMs). Recently, the antibody-drug conjugates (ADCs) sacituzumab govitecan (SG) and trastuzumab deruxtecan (T-DXd) have...
4.
Feasibility of targeted therapies in the adjuvant setting of early breast cancer in men: real-world data from a population-based registry
Frevert M, Dannehl D, Jansen L, Hermann S, Schaffler H, Huwer S, et al.
Arch Gynecol Obstet . 2024 Mar; 309(6):2811-2819. PMID: 38472501
Background: Following the positive iDFS and OS results of the phase III clinical trials monarchE, NATALEE and OlympiA, new oral anticancer agents (the CDK4/6 inhibitors abemaciclib, ribociclib as well as...
5.
Early breast cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
Loibl S, Andre F, Bachelot T, Barrios C, Bergh J, Burstein H, et al.
Ann Oncol . 2023 Dec; 35(2):159-182. PMID: 38101773
No abstract available.
6.
Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer
Geyer Jr C, Garber J, Gelber R, Yothers G, Taboada M, Ross L, et al.
Ann Oncol . 2022 Oct; 33(12):1250-1268. PMID: 36228963
Background: The randomized, double-blind OlympiA trial compared 1 year of the oral poly(adenosine diphosphate-ribose) polymerase inhibitor, olaparib, to matching placebo as adjuvant therapy for patients with pathogenic or likely pathogenic...
7.
Financial difficulties in breast cancer survivors with and without migration background in Germany-results from the prospective multicentre cohort study BRENDA II
Riccetti N, Felberbaum R, Flock F, Kuhn T, Leinert E, Schwentner L, et al.
Support Care Cancer . 2022 May; 30(8):6677-6688. PMID: 35507113
Purpose: We aimed to explore the trajectory of financial difficulties among breast cancer survivors in the German health system and its association with migration background. Methods: In a multicentre prospective...
8.
Current clinical practice and outcome of neoadjuvant chemotherapy for early breast cancer: analysis of individual data from 94,638 patients treated in 55 breast cancer centers
Ortmann O, Blohmer J, Sibert N, Brucker S, Janni W, Wockel A, et al.
J Cancer Res Clin Oncol . 2022 Apr; 149(3):1195-1209. PMID: 35380257
Neoadjuvant chemotherapy (NACT) is frequently used in patients with early breast cancer. Randomized controlled trials have demonstrated similar survival after NACT or adjuvant chemotherapy (ACT). However, certain subtypes may benefit...
9.
Prognostic relevance of the HER2 status of circulating tumor cells in metastatic breast cancer patients screened for participation in the DETECT study program
Muller V, Banys-Paluchowski M, Friedl T, Fasching P, Schneeweiss A, Hartkopf A, et al.
ESMO Open . 2021 Nov; 6(6):100299. PMID: 34839105
Background: Circulating tumor cells (CTCs) have been reported to predict clinical outcome in metastatic breast cancer (MBC). Biology of CTCs may differ from that of the primary tumor and HER2-positive...
10.
Diagnosis of presence and extent of deep infiltrating endometriosis by preoperative MRI-improvement of staging accuracy by expert training
Widschwendter P, Kohler M, Friedl T, Ammann B, Janni W, Rhomberg C, et al.
J Gynecol Obstet Hum Reprod . 2021 Sep; 51(1):102236. PMID: 34592437
Introduction: This study evaluates the clinical utility of magnetic resonance imaging (MRI) for the determination of presence and extent of DIE with special emphasis on effects of MRI reporting training...